ArticleBiosensors2025
Detecting Attomolar Concentrations of Interleukin IL-17A via Pollen-Based Nanoplasmonic Biochips.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- [Research progress on the application of pollen in the biomedical field].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Review
- Towards point-of-care tests for protein detection at the attomolar level via disposable pollen-based nanoplasmonic probes grafted with polymer-based receptors.Biomedical optics express · 2026Article
- An Eco-Friendly Disposable Plasmonic Biochip Based on Bacterial Cellulose for Interleukin-17A Detection at Atto-Femto Molar Level.ACS omega · 2026Article
- Point-of-Care Tests via Pollen-Based Nanoplasmonic Chips Combined with a Synthetic Receptor for FKBP12 Biomarker Detection at a Single-Molecule Level.ACS applied nano materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukins are involved in several diseases and cancers, and their detection and monitoring are of great interest. Their low abundance and short half-lives suggest the need to develop rapid, specific, and highly sensitive detection platforms, easily integrable in point-of-care (POC) systems. Among the other interleukins, interleukin IL-17A is associated with inflammations, neurodegenerative diseases, and cancers, and no biosensors have been previously reported for its detection. In this work, for the detection of IL-17A, a highly sensitive nanoplasmonic sensor based on natural nanostructures like pollen shells, covered by a gold film and a bio-receptor layer, is presented. Hybrid plasmonic modes are exploited to reach high sensitivity without using costly techniques to fabricate periodic nanostructures, such as electron beam lithography. A transparent amino-modified glass substrate is functionalized with carboxylic activated pollen via carbodiimide chemistry. Then, the pollen-based nanostructures are covered by a gold film and derivatized by an immuno-layer specific to IL-17A recognition. The developed IL-17A biosensor is monitored via a simple, small-sized, and low-cost experimental setup, demonstrating high selectivity, a fast response time of about five minutes, and sensitivity with a limit of detection in the ag/mL concentration range. The biosensor allows for the detection of IL-17A in complex solutions thanks to the possibility of high dilution, an advantageous aspect to POC systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.